Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.
Pecchi, S., Renhowe, P.A., Taylor, C., Kaufman, S., Merritt, H., Wiesmann, M., Shoemaker, K.R., Knapp, M.S., Ornelas, E., Hendrickson, T.F., Fantl, W., Voliva, C.F.(2010) Bioorg Med Chem Lett 20: 6895-6898
- PubMed: 21035331 
- DOI: https://doi.org/10.1016/j.bmcl.2010.10.021
- Primary Citation of Related Structures:  
3P2B - PubMed Abstract: 
PI3 Kinases are a family of lipid kinases mediating numerous cell processes such as proliferation, migration, and differentiation. The PI3 kinase pathway is often de-regulated in cancer through PI3Kα overexpression, gene amplification, mutations, and PTEN phosphatase deletion. PI3K inhibitors represent therefore an attractive therapeutic modality for cancer treatment. Herein we describe a novel series of PI3K inhibitors sharing a pyrimidine core and showing significant potency against class I PI3 kinases in the biochemical assay and in cells. The discovery, synthesis and SAR of this chemotype are described.
Organizational Affiliation: 
Novartis Institutes for Biomedical Research, Emeryville, CA, USA. sabina.pecchi@novartis.com